Indivior (INDV) Stock Price, News & Analysis

Company Overview

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine. The company is headquartered in Slough, United Kingdom, with a major operations and manufacturing hub in Richmond, Virginia. Since its inception, Indivior has sought to expand access to evidence-based treatments through ongoing clinical research and strategic collaborations.

Beyond its core opioid dependence offerings, Indivior maintains a pipeline of investigational therapies aimed at addressing alcohol use disorder and other psychiatric conditions. The company invests in clinical development programs to explore novel formulations, delivery technologies and digital health solutions intended to enhance treatment adherence and patient outcomes.

Today, Indivior markets its products across North America, Europe, Australia and other key regions, supporting healthcare professionals with educational and patient-support initiatives. Through its global footprint, the company aims to reduce barriers to care and improve long-term recovery rates for individuals affected by addiction worldwide.

Key Stats

• Today's Range: $22.47 to $23.63
• 50-Day Range: $15.14 to $24.98
• 52-Week Range: $7.33 to $25.10
• Volume: 1.44 million shs
• Average Volume: 1.84 million shs
• Market Capitalization: N/A
• P/E Ratio: 37.40
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Buy

Consensus Rating

Indivior has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Downside Risk

Indivior has a consensus price target of $22.00, representing about 5.1% downside from its current price of $23.19.

Amount of Analyst Coverage

Indivior has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 40.16%

Earnings Growth

Earnings for Indivior are expected to grow by 40.16% in the coming year, from $1.22 to $1.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 37.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.39.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 37.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.92.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.12% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indivior has recently increased by 17.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.12% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Indivior has recently increased by 17.77%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.38

News Sentiment

Indivior has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Indivior this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for INDV on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

MarketBeat Follows

4 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have not sold or bought any company stock.

Percentage Held by Institutions

60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INDV Stock Analysis - Frequently Asked Questions

How have INDV shares performed this year?

Indivior's stock was trading at $12.43 on January 1st, 2025. Since then, INDV shares have increased by 86.6% and is now trading at $23.19.

How were Indivior's earnings last quarter?

Indivior PLC (NASDAQ:INDV) announced its quarterly earnings results on Thursday, July, 31st. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.26 by $0.25. The company earned $302 million during the quarter, compared to analysts' expectations of $239.43 million. Indivior had a net margin of 6.65% and a negative trailing twelve-month return on equity of 86.28%.
Read the conference call transcript.

Who are Indivior's major shareholders?

Top institutional shareholders of Indivior include Two Seas Capital LP, Rubric Capital Management LP, Jefferies Financial Group Inc. and Scopia Capital Management LP.

How do I buy shares of Indivior?

Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Adobe (ADBE), AppLovin (APP), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 7/31/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 10/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INDV
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 1,051
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Indivior: $22.00
• High Price Target: $34.00
• Low Price Target: $13.00
• Potential Upside/Downside: -5.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.62
• Trailing P/E Ratio: 37.42
• Forward P/E Ratio: 19.02
• P/E Growth: N/A
• Net Income: $2 million
• Net Margins: 6.65%
• Pretax Margin: 15.60%
• Return on Equity: -86.28%
• Return on Assets: 16.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.90
• Quick Ratio: 0.76

Sales & Book Value

• Annual Sales: $1.19 billion
• Price / Sales: N/A
• Cash Flow: $1.82 per share
• Price / Cash Flow: 12.75
• Book Value: ($2.52) per share
• Price / Book: -9.21

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.81